###### Strengths and limitations of this study

Comprehensive search of two databases with independent study selection and data extraction.Included both observational and randomised studies in adults and/or children with asthma.Heterogenous nature of studies and the outcome measures which were available for analysis.Inability to properly assess differences between drugs, type of inhaler device or dose-responsiveness.

Introduction {#s1}
============

Asthma is a chronic inflammatory condition that affects both adults and children. There is a substantial body of evidence that suggest inhaled corticosteroids (ICS) are effective at controlling symptoms, improving lung function and reducing acute exacerbations.[@R1] They are therefore considered the gold standard first-line preventative therapy and are widely recommended in national and international guidelines.[@R2] [@R3]

However, long-term ICS use may be associated with adverse effects such as cataract, osteoporosis, fractures and reduction in growth velocity in children.[@R4] Concerns surrounding these potential harms may have a negative effect on ICS adherence, thus exposing patients to poorer asthma control and a potentially higher risk of needing oral corticosteroids for acute exacerbations.[@R4] Certain age groups, such as children or postmenopausal women may be particularly susceptible to adverse effects on bone metabolism and formation, and this therefore remains an area of concern for these patients.

The existing meta-analyses of ICS and bone adverse effects have usually included data from participants with chronic obstructive pulmonary disease (COPD)[@R5] and to date, there has been less focus on the effects in asthma alone. Patients with asthma may not share the same susceptibilities to osteoporosis as the patient with COPD because of differences in risk factors such as cigarette consumption, multimorbidity and nutritional problems that are prevalent in patients with COPD.[@R8] [@R9] It therefore remains unclear whether patients with asthma have a greater or lesser risk of bone adverse effects than those with COPD and a further review is necessary to clarify these risks for patients with asthma alone.

Hence we aimed to analyse the effects of long-term (≥12 months) ICS use in patients with asthma alone, concentrating on fracture and bone mineral density (BMD) outcomes.

Methods {#s2}
=======

Study selection criteria {#s2a}
------------------------

We aimed to focus on long-term, important but infrequent adverse effects on bone and as such, eligible studies had to have \>20 users of each ICS formulation, with follow-up of at least 12 months in duration.

Our inclusion criteria for RCTs were (1) parallel-group RCT; (2) participants with asthma of any severity; (3) ICS as the intervention versus a control treatment, where the comparison groups consisted of ICS versus other asthma therapy (or placebo), or ICS in combination with long-acting β-agonist (LABA) versus a LABA alone; and (4) stated aim to evaluate fractures or BMD.

We also evaluated controlled observational studies (case control, prospective cohort or retrospective cohort) reporting on risk of fractures or change in BMD with any ICS exposure compared to those without ICS exposure.

Exclusion criteria {#s2b}
------------------

We excluded studies that recruited mixed groups of participants (asthma/COPD) if the outcomes were not separately reported according to specific disease condition. We excluded crossover trials and studies that considered only oral corticosteroid use without reporting the effects of inhaled corticosteroids.

Search strategy {#s2c}
---------------

We initially searched MEDLINE and EMBASE in June 2013 using a broad strategy for a wide range of adverse effects potentially associated with ICS use, and we subsequently updated this through a more focused PubMed search in December 2014 (see eAppendix 1 for search terms and restrictions). We also manually looked through the bibliographies of included studies as well as existing systematic reviews for any other articles that may be potentially suitable.

Study selection {#s2d}
---------------

Two reviewers (MT and PB) independently, and in duplicate scanned all titles and abstracts and excluded articles that clearly were not RCTs or observational studies of ICS in patients with asthma. We proceeded to assess full-text versions of potentially relevant articles and conducted more detailed checks against our eligibility criteria, focusing on bone and fracture adverse effects. A third researcher (YKL or AMW) evaluated the decision on inclusion or exclusion in discussion with the two reviewers.

Study characteristics and data extraction {#s2e}
-----------------------------------------

We used preformatted tables to record study design and participant characteristics, definition of asthma, pharmacological agent (dose, device and frequency), and duration of follow-up. Two reviewers independently extracted data (MT and PB) on relevant outcomes, where we prespecified fracture risk of primary interest, and BMD at the lumbar spine or the femur as secondary end points. Any discrepancies were resolved through the involvement of a third reviewer (DG or YKL or AMW) after rechecking the source papers.

Risk of bias assessment {#s2f}
-----------------------

Two reviewers independently assessed the reporting of blinding of participants and personnel, randomisation sequence, allocation concealment, withdrawals and the loss to follow-up in RCTs. In order to assess validity of the associations between adverse effects and ICS use, we extracted information on participant selection, ascertainment of exposure and outcomes, and methods of addressing confounding in observational studies.[@R10]

We aimed to use a funnel plot and asymmetry testing to assess publication bias provided that there were more than 10 studies in the meta-analysis, and the absence of significant heterogeneity.[@R11]

Statistical analysis {#s2g}
--------------------

We pooled trial data using Review Manager (RevMan) V.5.3.2 (Nordic Cochrane Center, Copenhagen, Denmark). We used the inverse variance method to pool ORs for fracture events, and mean differences for BMD (g/cm^2^). In accordance with the recommendations of the Cochrane Handbook, we derived any SDs from 95% CIs or p values.[@R12] We assessed statistical heterogeneity using the I^2^ statistic with I^2^\>50% indicating a substantial level of heterogeneity.

If a trial had more than one group of non-ICS users as controls, we analysed data for ICS versus placebo (if available) in preference to data from active comparators such as ICS versus nedocromil, montelukast or disodium cromoglycate. If combination formulations were evaluated in the trial, we chose unconfounded comparisons based on ICS used together with the other drug versus other drug alone.

If a trial had several arms involving different ICS doses, we combined all the ICS arms together as recommended by the Cochrane Handbook.[@R13]

We did not have a pre-registered protocol.

Results {#s3}
=======

We screened 1887 potentially relevant articles, and finally included 18 studies in our systematic review (comprising 7 RCTs,[@R14]and 11 observational studies).[@R21] The process of study selection is shown in [figure 1](#BMJOPEN2015008554F1){ref-type="fig"}.

![Flow diagram of study selection. BMD, bone mineral density; RCT, randomised controlled trial.](bmjopen2015008554f01){#BMJOPEN2015008554F1}

[Table 1](#BMJOPEN2015008554TB1){ref-type="table"}A, B show the characteristics of the included RCTs, and the observational studies, respectively. [Tables 2](#BMJOPEN2015008554TB2){ref-type="table"} and [3](#BMJOPEN2015008554TB3){ref-type="table"} report on study validity and outcomes in adult and children, respectively.[](#BMJOPEN2015008554TB1a){ref-type="table"}[](#BMJOPEN2015008554TB2a){ref-type="table"}[](#BMJOPEN2015008554TB2b){ref-type="table"}[](#BMJOPEN2015008554TB3a){ref-type="table"}

###### 

Characteristics of included trials and observational studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(A\) Randomised controlled trials                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ----------------------------------------------------------------------------------------------------- --------------------------------------------- ------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------- ------ ------ -------------- ---------------------------------
  CAMP/Kelly *et al*[@R15] [@R32]                                                                       Multicentre US                                \>208 weeks   Mild-to-moderate asthma defined by symptoms or by use of inhaled bronchodilator ≥ twice weekly or daily medication for asthma. Airway methacholine challenge test                                                                                                                              BUD 200 µg bd (n=311)                                                                                58.2   9.0    93.6           40.5

  Nedocromil 8 mg daily (n=312)                                                                         66.0                                          8.8           93.4                                                                                                                                                                                                                                                                                           36.5                                                                                                                              

  Placebo (n=412)                                                                                       56.0                                          9.0           94.2                                                                                                                                                                                                                                                                                           35.9                                                                                                                              

  Ferguson *et al* 2007[@R14]                                                                           Multicentre---35 centres in 11 countries      52 weeks      Age 6--9 years persistent asthma ≥6 months; FEV~1~ ≥ 60% predicted; ↑PEFR of ≥15% after salbutamol. Exclusions: oral corticosteroids on \>2 occasions or \>12 days or \>210 mg prednisolone past 6 months; known growth disorder or glaucoma/cataracts                                         FP 100 μg bd (n=114)\                                                                                68     7.2    90.2           25% oral steroids past 6 months
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Diskus (dry powder inhaler)                                                                                                       

  BUD 200 μg bd (n=119)\                                                                                70                                            7.4           92.3                                                                                                                                                                                                                                                                                           21% oral steroids past 6months                                                                                                    
  Turbuhaler                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  Kemp *et al*[@R16]                                                                                    Multicentre US                                104 weeks     6-month history of mild asthma (FEV~1~ 82--85% predicted) able to be managed without steroids for 2 years                                                                                                                                                                                      FP 88 µg bd (n=55)\                                                                                  60     31.6   83             0
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Metered dose inhaler                                                                                                              

  FP 440 µg bd (n=51)\                                                                                  59                                            29.0          82                                                                                                                                                                                                                                                                                             0                                                                                                                                 
  Metered dose inhaler                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               

  Placebo (n=54)                                                                                        59                                            28.4          85                                                                                                                                                                                                                                                                                             0                                                                                                                                 

  Li *et al*[@R17]                                                                                      Multicentre US                                104 weeks     At least 6-month history with diagnosis using American Thoracic Society definition. FEV~1~ of ≥60% predicted, and limited previous corticosteroid therapy                                                                                                                                      FP 500 μg bd (n=32)\                                                                                 91     28.0   91             Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Diskhaler                                                                                                                         

  Placebo bd (n=32)\                                                                                    81                                            31.1          91                                                                                                                                                                                                                                                                                             Not reported                                                                                                                      
  Diskhaler                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          

  Maspero *et al*[@R18]                                                                                 50 centres worldwide                          52 weeks      Adults with \>3 months history of asthma, and not using ICS past 3 months. FEV~1~ between 60 and 90% predicted. Must have DEXA scan, and no evidence of low vitamin D                                                                                                                          Mometasone 400 µg daily (n=137)                                                                      34     30     76.5           7

  Mometasone 200 µg daily (n=140)                                                                       35                                            30            74.7                                                                                                                                                                                                                                                                                           7                                                                                                                                 

  FP 250 µg bd (n=147)                                                                                  39                                            28            75.3                                                                                                                                                                                                                                                                                           6                                                                                                                                 

  Montelukast 10 mg (n=142)                                                                             38                                            28            76.9                                                                                                                                                                                                                                                                                           10                                                                                                                                

  Roux *et al*[@R19]                                                                                    52 respiratory specialist clinics in France   104 weeks     Exacerbations ≥1×/week but \<1× daily; or chronic symptoms requiring daily treatment. Fulfilling: (1) FEV~1~ or PEFR ≥80% predicted; (2) reversibility ≥15%; (3) daily variability PEFR 20%--30% ≥2 days, or salbutamol use \>3 times previous week, or nocturnal symptoms ≥2× during run-in   FP 100 μg bd (n=87)\                                                                                 64     9.1    88.9           Not reported
                                                                                                                                                                                                                                                                                                                                                                                                                                                                   Diskus/Accuhaler dry powder inhaler                                                                                               

  Nedocromil 4 mg bd (n=87)\                                                                            66                                            9.4           88.5                                                                                                                                                                                                                                                                                           Not reported                                                                                                                      
  MDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Turpeinen *et al*[@R20]                                                                               Helsinki University Hospital, Finland         72 weeks      'Newly detected mild asthma'\                                                                                                                                                                                                                                                                  Continuous BUD (n=50) Turbuhaler\                                                                    60     6.9    Not reported   Not reported
                                                                                                                                                                    Excluded if history of inhaled, nasal or oral corticosteroid use in the previous 2 months before enrolment                                                                                                                                                                                     BUD 400 μg bd for 1 month, then 200 μg bd for 2nd--6th months, then 100 μg bd for final 12 months.                                

  BUD/placebo (n=44) Turbuhaler\                                                                        66                                            6.7           Not reported                                                                                                                                                                                                                                                                                   Not reported                                                                                                                      
  BUD 400 μg bd for 1st month, then 200 μg bd for 2nd to 6th months, then placebo for final 12 months                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                

  Sodium cromoglicate---10 mg tds for 18 months (unblinded) (n=42)\                                     50                                            7.0           Not reported                                                                                                                                                                                                                                                                                   Not reported                                                                                                                      
  MDI                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Bd, two times a day; BUD, budesonide; DEXA, dual-energy X-ray absorptiometry; FEV~1~, forced expiratory volume in 1 s; FP, fluticasone propionate; ICS, inhaled corticosteroids; MDI, metered dose inhaler; PEFR, peak expiratory flow rate.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(B\) Observational studies                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              
  ----------------------------- ------------------------------------------------------------- -------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------
  Agertoft and Pedersen[@R21]   Cross-sectional study                                         BMD                              Outpatient paediatric clinic, Kolding Hospital, Denmark\                                                                                 Selection of cases: Children with persistent asthma and no other chronic disease, on ICS continuously for ≥3 years.\                                                                                                                               BUD
                                                                                                                               157 cases, 111 controls                                                                                                                  Mean age: 10.3 years, male 69%, %FEV~1~ predicted: 97\                                                                                                                                                                                             
                                                                                                                                                                                                                                                                        Selection of controls: asthmatic children, who have never taken inhaled/systemic corticosteroids for \>2 weeks per year.\                                                                                                                          
                                                                                                                                                                                                                                                                        Mean age: 9.9 years, male 55%, %FEV~1~ predicted: 81                                                                                                                                                                                               

  Allen *et al*[@R22]           Prospective                                                   BMD                              Department of Paediatrics, Royal North Shore Hospital, Sydney, Australia\                                                                Selection of cases: prepubertal asthmatic children requiring \>3 courses oral corticosteroids within study period\                                                                                                                                 BDP, BUD
                                                                                                                               48 cases, 9 controls                                                                                                                     Mean age: 7.8 years, male 63%\                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                        Selection of controls: children not using corticosteroids.\                                                                                                                                                                                        
                                                                                                                                                                                                                                                                        Mean age: 8.4 years, male 78%                                                                                                                                                                                                                      

  Bahceciler *et al*[@R23]      Cross-sectional study                                         BMD                              Outpatient Allergy Clinic of Marmara University Hospital, Istanbul, Turkey\                                                              Asthma definition*:* mild intermittent plus persistent mild to moderate asthma\                                                                                                                                                                    BUD
                                                                                                                               52 cases, 22 controls                                                                                                                    Selection of cases: Children treated for ≥6 months.\                                                                                                                                                                                               
                                                                                                                                                                                                                                                                        Mean age: 6.4 years, male 42%\                                                                                                                                                                                                                     
                                                                                                                                                                                                                                                                        Characteristics of high-dose ICS group:\                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                        Mean age: 3 years\                                                                                                                                                                                                                                 
                                                                                                                                                                                                                                                                        Mean duration of disease: 50.4 months\                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                        Characteristics of low dose ICS group:\                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                        Mean age: 5.8 years\                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                        Mean duration of disease: 38.3 months\                                                                                                                                                                                                             
                                                                                                                                                                                                                                                                        Selection of controls: Age-matched asthmatic children who have never received ICS\                                                                                                                                                                 
                                                                                                                                                                                                                                                                        Mean age: 6.8 years, male 45%                                                                                                                                                                                                                      

  El *et al*[@R24]              Observational                                                 BMD                              Outpatients, Dokuz Eylul University, Balcova, Izmir, Turkey\                                                                             Asthma severity defined according to Global Initiative for Asthma guideline\                                                                                                                                                                       Not specified
                                                                                                                               45 cases, 46 controls                                                                                                                    Selection of cases: patients with mild or moderate asthma and regular ICS use. Mean age: 44.04 years, male 0%, %FEV~1~: 89.71\                                                                                                                     
                                                                                                                                                                                                                                                                        Controls : Mean age: 44.43 years, male 0%                                                                                                                                                                                                          

  Harris *et al*[@R25]          Cross-sectional study                                         BMD                              Outpatient clinics of Sydney Children\'s Hospital, Randwick, New South Wales and Monash Medical Centre, Clayton, Victoria, Australia.\   Selection of subjects:\                                                                                                                                                                                                                            BDP, BUD, FP
                                                                                                                               76 subjects                                                                                                                              Prepubertal asthmatic children stratified into groups according to corticosteroid treatment received in the past 6 months\                                                                                                                         
                                                                                                                                                                                                                                                                        1) no inhaled corticosteroid, mean age: 8.2 years, male 70%\                                                                                                                                                                                       
                                                                                                                                                                                                                                                                        2) moderate dose inhaled corticosteroid (400--800 μg/day), mean age: 7.4 years, male 56%\                                                                                                                                                          
                                                                                                                                                                                                                                                                        3) high-dose inhaled corticosteroid (\>800 µg/day), mean age: 8.9 years, male 75%,                                                                                                                                                                 

  Johannes *et al*[@R26]        Nested case-control study                                     Risk of non-vertebral fracture   Ingenix Epidemiology---Research database of United Healthcare members, 17 states in the USA.\                                            Adults ≥40 years age, in health plan for ≥12 continuous months Jan 1997 to Jun 2001, with ICD-9 code for asthma, or COPD\                                                                                                                          BDP, BUD, FP flunisolone, triamcinolone
                                                                                                                               1722 cases, 17 220 controls                                                                                                              Selection of cases: Non-vertebral fractures by ICD-9 codes, with claim for treatment (including inpatient hip fractures)\                                                                                                                          
                                                                                                                                                                                                                                                                        Mean age 52.9 years, male 29.4%\                                                                                                                                                                                                                   
                                                                                                                                                                                                                                                                        Selection of controls:\                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                        Sampled from person-time of respiratory cohort by two-tiered random sampling with replacement\                                                                                                                                                     
                                                                                                                                                                                                                                                                        Mean age 52.2 years, male 41.1%                                                                                                                                                                                                                    

  Schlienger *et al*[@R27]      Retrospective Population-based nested case-control analysis   Fracture risk                    UK General Practice Research Database\                                                                                                   Aged 5--79 years with ICD code for asthma or COPD with ≥1 prescription for ICS and/or OCS; or with no exposure to corticosteroids\                                                                                                                 76.2% BDP\
                                                                                                                               3744 cases, 21 757 controls                                                                                                              From there 65 779 individuals aged 5--17 years identified to form base population for study\                                                                                                                                                       21.7% BUD\
                                                                                                                                                                                                                                                                        Selection of cases: Patients with 1st-time diagnosis ICD-8 bone fracture; male 65.6%\                                                                                                                                                              2.1% FP
                                                                                                                                                                                                                                                                        Selection of controls: Up to 6 control subjects selected per case, matched on age, gender, general practice attended, calendar time and years of history in GPRD; male 64.9%                                                                       

  Sosa *et al*[@R28]            Cross-sectional study                                         BMD; Fracture risk               Canary Islands, Spain\                                                                                                                   Selection of cases: Women suffering from stable bronchial asthma, treated with ICS ≥1 year, and who did not receive oral or parenteral steroids. Mean age: 53.0 years, number of menopausal subjects n (%): 65 (61.9)\                             ICS formulations not specified
                                                                                                                               105 cases; 133 controls                                                                                                                  Selection of controls: weight-matched women, no asthma and no steroids. Controls were usually friends or neighbours of the patients. Mean age: 49.7 years, number of menopausal subjects n (%): 74 (57.8)                                          

  Van Staa *et al*[@R29]        Population-based cohort study/nested case-control analysis    Fracture risk                    UK General Practice Research Database (GPRD)\                                                                                            Children aged 4--17 years old, on ICS. 3 study groups: selection of cases: non-vertebral fracture. Male 61%, 8856 (36.9%) aged 4--9 years, 8496 (35.4%) aged 10--13 years, 6632 (27.7%) aged 14--17 years\                                         BDP, BUD, FP
                                                                                                                               Cohort: ICS users: 97 387\                                                                                                               Selection of controls: for each fracture case, one control patient randomly selected, matched by age, sex, GP practice and calendar time. Male 61%, 8861 (36.9%) aged 4--9 years, 8497 (35.4%) aged 10--13 years, 6626 (27.6%) aged 14--17 years   
                                                                                                                               Bronchodilators only: 70 984\                                                                                                                                                                                                                                                                                                                                                               
                                                                                                                               Controls: 345 758\                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                               Fracture cases: 23 984; Controls: 23 984                                                                                                                                                                                                                                                                                                                                                    

  Wisniewski *et al*[@R30]      Cross-sectional study                                         BMD                              Asthma register and local general practices in Nottingham, UK\                                                                           Selection of cases: aged 20--40 years with documented history of asthma:\                                                                                                                                                                          BDP, BUD
                                                                                                                               47 cases; 34 controls                                                                                                                    Group 1: asthmatics using inhaled β~2~-agonist only. Males 56%, mean age: men 30.3 years; women 25.6 years, mean FEV~1~ (litres): men 3.87; women 3.13\                                                                                            
                                                                                                                                                                                                                                                                        Group 2: ICS use ≥5 years with no systemic steroids in the past 6 months. Males 40%, mean age: men 32.3 years; women 32 years, mean FEV~1~ (litres): men 3.40; women 2.83                                                                          

  Yanik *et al*[@R31]           Observational                                                 BMD                              Pulmonology outpatient clinic at Fatih University Faculty of Medicine, Ankara, Turkey\                                                   Selection of cases: Regular ICS use ≥12 months) as defined by The Global Initiative for Asthma (GINA) criteria\                                                                                                                                    BDP, BUD, FP
                                                                                                                               46 cases, 60 controls                                                                                                                    Mean age: 62.5 years, male 0%, %FEV~1~ predicted: 83.1, All cases were postmenopausal\                                                                                                                                                             
                                                                                                                                                                                                                                                                        Selection of controls: healthy postmenopausal females. Mean age: 63 years                                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BDP, beclomethasone dipropionate; BUD, budesonide; COPD, chronic obstructive pulmonary diseases; FEV~1~, forced expiratory volume in 1 s; FP, fluticasone propionate; GP, general practitioner; ICD, International Classification of Diseases; ICS, inhaled corticosteroids.

###### 

Study validity and outcomes (bone mineral density and fractures) in children

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(A\) RCTs of inhaled corticosteroids---children                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  -------------------------------------------------- -------------------------------------------------------- -------------------------------- ---------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ----------------------------
  CAMP/Kelly *et al*[@R15] [@R32]                    Permuted blocks, stratified                              Adequate                         Adequate                                       Height recorded at every visit; BMD once every year                                                                                                           Fracture rate (adjusted for age, ethnic group, sex, clinic, base line duration, skin-test reactivity and asthma severity):\   11%                                5%
                                                                                                                                                                                                                                                                                                                                                            BUD: 5.7 per 100 person-years\                                                                                                                                   
                                                                                                                                                                                                                                                                                                                                                            Placebo: 5.1 per 100 person-years\                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                            p=0.59\                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                            Mean difference in BMD (ICS vs placebo):\                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                            Females: −0.001 (derived SE 0.0016)\                                                                                                                             
                                                                                                                                                                                                                                                                                                                                                            Male:−0.003 (derived SE 0.0014)                                                                                                                                  

  Ferguson *et al* 2007[@R14]                        Not reported                                             Remote computerised allocation   Adequate                                       Lumbar-spine BMD assessed at beginning and end of treatment with DEXA scan                                                                                    Mean difference in lumbar spine BMD for FP vs BUD: 0.0075 (95% CI −0.033 to 0.048)                                            90% patients received \>40 weeks   26% did not reach 51 weeks

  Roux *et al*[@R19]                                 Central Block randomisation with gender stratification   .                                Largely open. Analysis of DEXA scans blinded   Lumber spine and femoral neck BMD (DEXA) during run-in and 6, 12 and 24 months. Adjusted for age, height, weight, baseline BMD, gender and measuring device   Mean difference in lumbar spine BMD for FP vs control: 0.012 (SE 0.0073); values calculated from % change in manuscript       23%                                4%

  Turpeinen *et al*[@R20]                            Block                                                    Unclear                          Blinded for budesonide and placebo arms        BMD of L1--4 measured by radiologist using DEXA at baseline and at 18 months                                                                                  Mean change in lumbar spine BMD:\                                                                                             20%                                3%
                                                                                                                                                                                                                                                                                                                                                            Budesonide for 12 months 0.023 (SD 0.022)\                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                            Placebo for 12 months 0.029 (SD 0.022)\                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                            DSCG: 0.034 (SD 0.022)                                                                                                                                           
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BUD, budesonide; DEXA, dual-energy X-ray absorptiometry; DSCG, disodium cromoglicate; FP, fluticasone propionate.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(B\) Observational studies of bone mineral density and fractures---children                                                                                                                                                                                                                                                                                                                        
  ------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------- -------------------------------------- ------------------------------------------------------------ ----------------------------------------------------- -------------------------------------- ----------------------------------------------------
  Agertoft and Pedersen[@R21]                                                    DEXA scan at one visit, performed by same investigator blinded to treatment group                                   Compliance checked: Good\              Asthmatic children with ICS use continuously for ≥3 years\   Log of accumulated dose of BUD; gender; age           Mean ICS BUD dose 504 μg (daily)       Mean BMD:\
                                                                                                                                                                                                     Duration:\                             Type of inhaler: MDI; Turbuhaler\                                                                                                                         BUD group: 0.92\
                                                                                                                                                                                                     Mean 1603 days                         Type of steroid: BUD                                                                                                                                      Control group: 0.92

  Allen *et al*[@R22]                                                            DEXA scan at baseline and again at 9--20 months later. Value for 12-month time point calculated with all outcomes   Compliance checked: Adequate\          Type of inhaler: Spacer, Turbohaler\                         Age; height; weight; dose of inhaled corticosteroid   Mean ICS dose 0.67±0.48 mg/m^2^/day    Change in mean vertebral BMD (SD) over 12 months:\
                                                                                                                                                                                                     Duration of follow-up: 9--20 months    Type of steroid: BDP, BUD                                                                                                                                 ICS group (n=47): 0.03±0.03\
                                                                                                                                                                                                                                                                                                                                                                                                      Control group (n=9): 0.06±0.04\
                                                                                                                                                                                                                                                                                                                                                                                                      p:\<0.025

  Bahceciler *et al*[@R23]                                                       Anteroposterior (AP) spine (L2--4) by DEXA scan                                                                     Compliance: not reported\              Use of BUD as MDI ≥6 months                                  None                                                  ICS Mean daily dose (SD): 419±154 μg   Mean lumbar spine BMD:\
                                                                                                                                                                                                     Follow-up: 13.0±9.8 months                                                                                                                                                                       ICS group: 0.593 (SD 0.122)

  Control                                                                        Mean lumbar spine BMD: 0.579 (SD 0.156)                                                                                                                                                                                                                                                                              

  Harris *et al*[@R25]                                                           Lumbar spine by DEXA                                                                                                Compliance checked: not reported\      Stratified by treatment in past 6 months\                    Weight                                                0 μg/day                               Mean lumbar spine BMD (SD) 0.68 (0.07)
                                                                                                                                                                                                     Duration of follow-up: 3.5±2.4 years   Type of inhaler: Spacer device\                                                                                                                           
                                                                                                                                                                                                                                            Type of steroid: BDP*,*BUD, FP                                                                                                                            

  400--800 μg/day                                                                Mean lumbar spine BMD (SD)\                                                                                                                                                                                                                                                                                          
                                                                                 0.70 (0.08)                                                                                                                                                                                                                                                                                                          

  \>800 μg/day                                                                   Mean lumbar spine BMD (SD)\                                                                                                                                                                                                                                                                                          
                                                                                 0.67 (0.08)                                                                                                                                                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Studies reporting on fracture risk   Fracture outcomes                                                                                                                                                                                                                                                                                                                                                                                                                                                             
  ------------------------------------ -------------------------------------------------------------------- ------------------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------- ----------------------------------
  Schlienger *et al*[@R27]             Identified by ICD-8 codes 800.x −829.x, from computerised records\   Compliance checked: not reported\                                                     ICS use in UK General Practice Research Database\   Matched for age, gender, general practice, calendar time, years in GPRD Adjusted for comorbidities: chronic renal failure, hyperthyroidism, hyperparathyroidism, inflammatory bowel disease, malnutrition, malabsorption\   1--9 prescriptions Cases: n=332\   Adjusted OR: 0.97 (0.85 to 1.11)
                                       Cases=1st-time diagnosis of bone fracture\                           Duration:\                                                                            Type of inhaler: not reported\                      Medications: asthma drugs, psychotropic drugs, antihypertensives, calcium, fluoride, vitamin D                                                                                                                              Controls: n=2017                   
                                       Controls---no fracture                                               Median number of prescriptions: 26, corresponds to \>7 years of continuous exposure   Type of steroid: BDP, BUD, FP                                                                                                                                                                                                                                                                                      

  10--19 prescriptions Cases: n=124\   Adjusted OR: 1.08 (0.87 to 1.33)                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Controls: n=682                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  ≥20 prescriptions Cases: n=88\       Adjusted OR: 1.15 (0.89 to 1.48)                                                                                                                                                                                                                                                                                                                                                                                                                                              
  Controls: n=422                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    

  All ICS users combined               Adjusted OR: 1.01 (0.90 to 1.13)                                                                                                                                                                                                                                                                                                                                                                                                                                              

  Van Staa *et al*[@R29]               Ascertained from diagnoses within computer records                   Compliance not reported\                                                              Current users of ICS\                               History of seizures; use of non-steroidal anti-inflammatory drugs or bronchodilators; hospitalisation for asthma past 2 years; number of prescriptions in past year. Age; sex                                               200 μg                             Adjusted OR: 0.96 (0.83 to 1.12)
                                                                                                            Start of follow-up:1987 onwards or from age 4 years\                                  Type of inhaler: not reported\                                                                                                                                                                                                                                                                                     
                                                                                                            End: December 1997 or age 18 years                                                    Type of inhaled steroid: BDP, BUD, FP                                                                                                                                                                                                                                                                              

  201--400 μg                          Adjusted OR: 1.07 (0.93 to 1.24)                                                                                                                                                                                                                                                                                                                                                                                                                                              

  \>400 μg                             Adjusted OR: 1.17 (0.93 to 1.45)                                                                                                                                                                                                                                                                                                                                                                                                                                              

  All ICS users                        Adjusted OR: 1.03 (0.93 to 1.15)                                                                                                                                                                                                                                                                                                                                                                                                                                              
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BDP, beclometasone diproprionate; BUD, budesonide; DEXA, dual-energy X-ray absorptiometry; FP, fluticasone propionate; ICD, International Classification of Disease; ICS, inhaled corticosteroids; MDI, metered dose inhaler.

###### 

Study validity and outcomes (bone mineral density and fractures) in adults

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  \(a\) RCTs of inhaled corticosteroids---adults                                                                                                                                                                                                                                                                                                      
  ------------------------------------------------ ------------------------------------------------------------------ ---------- ---------- ----------------------------------------------------------------------------------------------------------------------------- ------------------- --------------------------------------------- --------- --------
  Kemp *et al*[@R16]                               Random code with blinded labels                                    Adequate   Adequate   DEXA scan every 6 months at lumbar spine (L1-L4). analysed by central osteoporosis research facility for quality assurance\   FP 88 µg bd         At week 104\                                  17 (31)   6 (11)
                                                                                                                                            Adjusted for baseline value, investigator, sex, age                                                                                               1) Lumbar spine: 0.008, SE 0.006\                       
                                                                                                                                                                                                                                                                                              2) Proximal femur: −0.009, SE 0.009                     

  FP 440 µg bd                                     At week 104\                                                       18 (35)    7 (14)                                                                                                                                                                                                               
                                                   1) lumbar spine: -0.003, SE 0.008\                                                                                                                                                                                                                                                                 
                                                   2) Proximal femur: −-0.020, SE 0.009                                                                                                                                                                                                                                                               

  Placebo bd                                       At week 104\                                                       10 (19)    4 (7)                                                                                                                                                                                                                
                                                   1) Lumbar spine: 0.001, SE 0.005\                                                                                                                                                                                                                                                                  
                                                   2) Proximal femur: −0.007, SE 0.007                                                                                                                                                                                                                                                                

  Li *et al*[@R17]                                 Unclear                                                            Unclear    Adequate   DEXA at L1-L4 of lumbar spine. Measured at screening and 6-month intervals                                                    FP                  At week 104, lumbar spine: −0.006, SE 0.008   9 (28)    2 (6)

  Placebo                                          At week 104, lumbar spine: −0.007, SE 0.010                        8 (25)     7 (22)                                                                                                                                                                                                               

  Maspero *et al*[@R18]                            Centrally administered through interactive voice response system   Adequate   Adequate   DEXA at L1-L4 of lumbar spine. Follow-up at 26 and 52 weeks                                                                   Mometasone 400 µg   1\) Lumbar spine: 0.0092) Femur: 0.004        34 (25)   5 (3)

  Mometasone 200 µg daily                          1\) Lumbar spine: 0.0082) Proximal femur: 0.004                    35 (25)    7 (4)                                                                                                                                                                                                                

  FP 250 µg bd                                     1\) Lumbar spine: 0.0122) Femur: −-0.005                           38 (26)    4 (3)                                                                                                                                                                                                                

  Combined estimate for all ICS users              1\) Lumbar spine: 0.0092) Femur: 0.0008                            107 (25)   16 (4)                                                                                                                                                                                                               

  Montelukast 10 mg daily                          1\) Lumbar spine: 0.0132) Femur: −0.002                            31 (22)    3 (3)                                                                                                                                                                                                                
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AE, adverse event; bd, two times a day; DEXA, dual-energy X-ray absorptiometry; FP, fluticasone propionate; ICS, inhaled corticosteroids; RCT, randomised controlled trial.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Observational studies of bone mineral density and fractures---adults                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  ---------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------ ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ --------------------------------- ---------------------------------------------
  El *et al*[@R24]                                                       DEXA lumbar spine (L1--4) and femoral neck                                                                                     Compliance checked: poor\                                    Regular ICS \>6 months\                                                                  Age                                                                                                                                                    Cases\                            Mean lumbar*:* 0.925, SD 0.211\
                                                                                                                                                                                                        Duration:\                                                   Type of inhaler: not reported\                                                                                                                                                                                                                  Mean daily ICS dose 326.43 µg     Mean femoral neck: 0.746, SD 0.127
                                                                                                                                                                                                        mean duration (SD) (years): 2.79±1.77                        Type of ICS: not reported                                                                                                                                                                                                                                                         

  Controls (no exposure)                                                 Mean lumbar: BMD: 0.927, SD 0.229\                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                         Mean femoral neck: 0.792, SD 0.097                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Johannes *et al*[@R26]                                                 Non-vertebral identified by ICD-9 codes and insurance claim for fracture treatment within 2 weeks                              Compliance checked: not reported\                            ICS use from pharmacy claims in the 365 days before index date.\                         Demographics---age, sex, region, time and season\                                                                                                      1--167 μg                         OR 1.00\
                                                                                                                                                                                                        Duration: 1 Year ICS exposure                                Type of inhaler: not reported\                                                           Comorbidities---wide range of cardiovascular, endocrine, metabolic and musculoskeletal conditions\                                                                                       95% CI 0.84 to 1.18
                                                                                                                                                                                                                                                                     Type of steroid: BDP, BUD, FP, flunisolone, triamcinolone                                Medications---oral corticosteroids, bisphosphonates, statins, anticonvulsants, oestrogen, raloxifene, calcitonin\                                                                        
                                                                                                                                                                                                                                                                                                                                                              Healthcare utilisation for underlying respiratory disease                                                                                                                                

  168--504 μg                                                            OR: 1.02\                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                         95% CI 0.83 to 1.26                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  505--840 μg                                                            OR: 1.14\                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
                                                                         95% CI 0.80 to 1.62                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  \>840 μg                                                               0.99\                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
                                                                         95% CI 0.66 to 1.50                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  Sosa *et al*[@R28]                                                     DEXA\                                                                                                                          Compliance: not reported\                                    ICS for \>1 year\                                                                        Age                                                                                                                                                    Cases (dose not reported)         Lumbar spine: 0.960; 95% CI 0.925 to 0.995\
                                                                         lumbar spine (L2-L4) and proximal femur                                                                                        Duration of follow up: Median treatment with ICS: 10 years   Type of inhaler: not reported\                                                                                                                                                                                                                                                    Femoral neck:0.776; 95% CI 0.750 to 0.802\
                                                                                                                                                                                                                                                                     Type of ICS: not reported                                                                                                                                                                                                                                                         Fractures: 22/105 (21.0%)

  Controls                                                               Lumbar spine: 0.991; 95% CI 0.960 to 1.022\                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                         Femoral neck: 0.780; 95% CI 0.758 to 0.803\                                                                                                                                                                                                                                                                                                                                                                                                                                   
                                                                         Fractures: 9/133 (7.0%)                                                                                                                                                                                                                                                                                                                                                                                                                                                       

  Wisniewski *et al*[@R30]                                               Posterior-anterior spine (L2--4), lateral spine (body of L3) measured by DEXA once. All scans by same radiographer (blinded)   Compliance checked: Adequate\                                ICS for \> 5 years\                                                                      age; weight; smoking; alcohol; activity grade; asthma severity; age at menarche; lifetime total dose of oestrogen and progesterone; prednisolone use   Cases                             Lumbar spine±SD\
                                                                                                                                                                                                        Duration:\                                                   Type of inhaler: Metered dose inhaler---36 patients; dry powder inhaler---11 patients\                                                                                                                                                                                            Men : 1.28±0.13; Women: 1.04±0.14\
                                                                                                                                                                                                        Median duration of use of ICS (years)\                       Type of ICS: BDP, BUD                                                                                                                                                                                                                                                             Femoral neck±SD:\
                                                                                                                                                                                                        Men: 9.00\                                                                                                                                                                                                                                                                                                                                     Men : 1.17±0.18; Women: 1.09±0.14\
                                                                                                                                                                                                        Women: 6.29                                                                                                                                                                                                                                                                                                                                    Vertebral fractures overall: 2/47

  Controls (No exposure)                                                 Lumbar spine±SD\                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                         Men:1.21±0.17*;* Women: 1.25±0.12\                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                         Femoral neck±SD:\                                                                                                                                                                                                                                                                                                                                                                                                                                                             
                                                                         Men : 1.04±0.14; Women: 1.10±0.14\                                                                                                                                                                                                                                                                                                                                                                                                                                            
                                                                         Vertebral fractures overall: 6/34                                                                                                                                                                                                                                                                                                                                                                                                                                             

  Yanik *et al*[@R31]                                                    DEXA lumbar spine and hip (femoral neck and trochanter).\                                                                      Compliance checked: Adequate\                                Regular ICS \>12 months\                                                                 None                                                                                                                                                   Cases (total)\                    Lumbar spine± SD\
                                                                         Patient-reported history of fractures                                                                                          Duration of Follow-up: 4.3±2.6 years                         Type of inhaler: Not reported\                                                                                                                                                                                                                  Mean daily ICS dose (μg) (SD):\   0.95±0.29\
                                                                                                                                                                                                                                                                     Type of ICS:\                                                                                                                                                                                                                                   324.9±121.8                       Femoral neck± SD\
                                                                                                                                                                                                                                                                     BDP, BUD, FP                                                                                                                                                                                                                                                                      0.83±0.12\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Atraumatic vertebral fractures: 4 (8.6%)

  Controls                                                               Lumbar spine±SD\                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                         0.88±0.14\                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                         Femoral neck±SD\                                                                                                                                                                                                                                                                                                                                                                                                                                                              
                                                                         0.74±0.23\                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
                                                                         Atraumatic vertebral fracture: 6 (10%)                                                                                                                                                                                                                                                                                                                                                                                                                                        
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BDP, beclometasone diproprionate; BUD, budesonide; DEXA, dual-energy X-ray absorptiometry; FP, fluticasone propionate; ICD, International Classification of Disease; ICS, inhaled corticosteroids.

Four of the RCTs focused solely on children,[@R14] [@R15] [@R19] [@R20] while the remaining three were in adults.[@R16] Treatment duration was up to 4 years in one study,[@R15] while the remaining six trials had ICS therapy for between 52 and 104 weeks. Intervention arms of the trials included fluticasone (5 trials), budesonide (3 trials) and mometasone (one trial). Fluticasone and mometasone were the ICS used in the intervention arms of one trial, and in this trial, we evaluated the results of all ICS users combined against montelukast.[@R18]

Five of the observational studies focused solely on children,[@R21] [@R25] [@R29] while the remainder looked at adults or a mixture of age groups. The observational studies looked at wider range of ICS than the RCTs, with the inclusion of beclometasone, flunisolide and triamcinolone users.

Study validity {#s3a}
--------------

Validity assessment of the included studies is reported in [tables 2](#BMJOPEN2015008554TB2){ref-type="table"} and [3](#BMJOPEN2015008554TB3){ref-type="table"}.

### Randomised controlled trials (n=7) {#s3a1}

Overall, four of the RCTs reported an appropriate method of sequence generation, while five provided details on how concealment of allocation was achieved. With regards to blinding, five trials reported the use of double-blinding. Ascertainment of BMD was consistently performed through dual-energy X-ray absorptiometry (DEXA) scans, but the trials did not state how and when fracture diagnoses were confirmed. One major limitation that affected all the trials stemmed from discontinuations and substantial losses to follow-up for measurement of BMD outcomes at final time-points.

### Observational studies (n=11) {#s3a2}

We felt that only four studies took account of a good range of variables when tackling baseline confounding.[@R26] [@R27] [@R29] [@R30] Assessment of compliance or adherence to ICS use was reported in four studies.[@R21] [@R22] [@R30] [@R31] Fracture events were typically recorded through administrative codes while one study relied on patient self-report. Ascertainment of BMD was through DEXA scans. Overall, we felt that most of the studies were at moderate to high risk of bias due to the above limitations, with four studies possibly of slightly better methodological quality because of adequate outcome ascertainment and adjustment for confounders.[@R26] [@R27] [@R29] [@R30]

Fractures with ICS {#s3b}
------------------

We identified one large long-term RCT in children that reported adjusted fracture rate of 5.7 per 100 patient years with budesonide as compared to 5.1 per 100 patient years with placebo (p=0.53).[@R32] Similarly, there was no significant increase in likelihood of fracture in a meta-analysis of two observational studies in children, (OR 1.02, 95% CI 0.94 to 1.10, I^2^=0%)[@R27] [@R29] as shown in [figure 2](#BMJOPEN2015008554F2){ref-type="fig"}. The point estimates of fracture risk was not significantly elevated at higher dose levels, with one study demonstrating an OR of 1.15 (0.89 to 1.48) for children with ≥20 prescriptions,[@R27] and the other study reporting an OR of 1.17 (0.93 to 1.45) for children using a daily dose of \>400 μg beclomethasone dipropionate equivalents.[@R29]

![Fracture risk, ICS use versus non-use. ICS, inhaled corticosteroids.](bmjopen2015008554f02){#BMJOPEN2015008554F2}

No consistent association between ICS use and fracture risk in adults was seen in the pooled estimate from four observational studies (overall OR 1.09, 95% CI 0.45 to 2.62; [figure 2](#BMJOPEN2015008554F2){ref-type="fig"}).[@R26] [@R28] [@R30] [@R31] There was substantial heterogeneity in this meta-analysis (I^2^=76%), with Sosa\'s study reporting significantly increased fracture risk,[@R28] while the others did not.

However, we judged a study by Sosa *et al*[@R28] to be at high risk of bias because the control group consisted of relatives and neighbours of patients, the type of ICS was not reported and there were no statistical adjustments for confounders. In this data set, Johannes *et al*[@R26] was the only study reporting fractures according to dose, but this did not demonstrate any consistent trend towards elevated risk at higher doses.

Lumbar spine BMD {#s3c}
----------------

Three RCTs and three observational studies reported on comparative change at the lumbar spine in children.[@R15] [@R19] [@R20] [@R22] [@R23] [@R25] ([figure 3](#BMJOPEN2015008554F3){ref-type="fig"}) ICS use was not associated with significant reductions in BMD as compared to controls in RCTs (mean difference −0.0018 g/cm^2^; 95% CI −0.0051 to 0.0015 g/cm^2^; I^2^=46%) or observational studies (mean difference −0.0075 g/cm^2^; 95% CI −0.044 to 0.028 g/cm^2^; I^2^=42%). There was no clear signal of dose responsiveness in one observational study that separated participants into different dose levels,[@R25] whereas one RCT suggested that longer term users of budesonide with greater cumulative doses had lower BMD compared to those who received lower cumulative doses.[@R20]

![BMD in lumbar spine children, ICS use versus non-use. BMD, bone mineral density; ICS, inhaled corticosteroids.](bmjopen2015008554f03){#BMJOPEN2015008554F3}

Three RCTs and four observational studies reported on comparative change in BMD at the lumbar spine in adults ([figure 4](#BMJOPEN2015008554F4){ref-type="fig"}).[@R16] [@R24] [@R28] [@R30] [@R31] ICS use was not associated with significant reductions in BMD as compared to controls in RCTs (mean difference −0.0019 g/cm^2^; 95% CI −0.0075 to 0.0038 g/cm^2^; I^2^=0%) or observational studies (mean difference −0.0055 g/cm^2^; 95% CI −0.047 to 0.058 g/cm^2^; I^2^=45%).

![BMD in adults, ICS use versus non-use. BMD, bone mineral density; ICS, inhaled corticosteroids; RCT, randomised controlled trial.](bmjopen2015008554f04){#BMJOPEN2015008554F4}

Femur/hip BMD for adults {#s3d}
------------------------

There were three RCTs and four observational studies reporting comparative change in BMD at the femur or hip in adults ([figure 4](#BMJOPEN2015008554F4){ref-type="fig"}).[@R16] [@R24] [@R28] [@R30] [@R31] ICS use was not associated with significant reductions in BMD as compared to controls in RCTs (mean difference 0.0020 g/cm^2^; 95% CI −0.0030 to 0.0070 g/cm^2^; I^2^=0%) or observational studies (mean difference 0.0070 g/cm^2^; 95% CI −0.045 to 0.059 g/cm^2^; I^2^=73%).

There was sparse data comparing different ICS molecules head to head. Ferguson *et al*[@R14] measured lumbar spine BMD and reported a non-significant finding between children randomised to fluticasone propionate 100 μg twice daily as compared to budesonide, mean difference 0.0075 g/cm^2^ (95% CI −0.033 to 0.048 g/cm^2^). Maspero conducted a five arm trial that included mometasone and fluticasone propionate in adults. There were no significant differences in lumbar spine and femur BMD between the two compounds at the end of the trial.[@R18]

We did not proceed to constructing a funnel plot for detection of publication bias because we had less than 10 studies in the meta-analysis of each outcome, and there was substantial heterogeneity.

Discussion {#s4}
==========

We focused our systematic review of RCTs and observational studies on skeletal adverse effects of ICS in patients with asthma. We did not find convincing evidence of increased fracture risk with ICS use in adults or children. Equally, there was no consistent evidence of any significant detrimental relationship between ICS use and BMD at the lumbar spine (in adults and children) or femur (in adults). There was insufficient data for us to detect any dose--response relationship, or to judge any potential differences between the available ICS molecules.

Our findings should be contrasted with those of other recent published reviews. There have been at least four systematic reviews evaluating fractures or BMD in ICS users, with two earlier reviews demonstrating a significant reduction in BMD but no definite impact on fractures.[@R5] [@R33] The most recent meta-analyses have identified a small but statistically significant dose-related increase in risk of fracture associated with ICS use in patients with COPD.[@R6] [@R7] Our findings differ from these other reviews as we have specifically focused on ICS use in patients with asthma. Here, we used very rigid selection criteria in an attempt to exclude patients with COPD from our meta-analysis.

The deleterious effects of ICS on BMD seen in previous meta-analyses could be explained in part by the higher prevalence of smoking in patients with COPD as previous studies have shown that smoking has a harmful effect on BMD, and increasing fracture risk.[@R8] In addition, as a group, patients with asthma are likely to be younger and to have fewer comorbidities than those with COPD which may impact on BMD and fracture risk. Recent research indicates that multimorbidity (including cachexia and low-grade systemic inflammation) is often seen in patients with COPD,[@R9] and it is conceivable that these factors may have a further negative impact on bone formation that accentuate the risks of ICS in COPD.

ICS therapy may have a positive impact on bone density through reduction of chronic inflammation and avoidance of need for acute short courses of oral corticosteroids during exacerbations. In addition, ICS may allow better control of asthma in patients such that they become more active, thereby slowing or preventing steroid-induced osteoporosis through the beneficial effects of physical activity on BMD. Bone mass can also be influenced by a wide range of other factors (such as nutrition, genetic make-up, endocrine status and amount of physical exercise),[@R1] and ICS may therefore not be the most important influence on bone density in patients with asthma.

There are a number of limitations to our systematic review. Our search was limited to English language articles. Although, studies have attempted to assess skeletal adverse effects in many different ways, we have limited our review to clinically meaningful outcomes such as BMD in g/cm^2^ at lumbar spine and femur, and fractures. We did not have sufficient data from the primary studies for us to conduct meaningful analyses on different combinations of drug compounds, inhaler devices and dosage regimens. Some of the included studies were published more than a decade ago, and advances in asthma care may have made their findings less applicable to current-day patients. We recognise that there is potential for risk of bias (stemming from substantial loss to follow-up for BMD measurements) within this data set. Hence, we are unable to interpret the effects of ICS in very long-term use of ICS over a decade or more.

Our systematic review demonstrates that there is no consistent evidence of serious skeletal harm from use of ICS. Although there are intrinsic limitations to the evidence, we believe that our systematic review provides some reassurance to patients and prescribers of ICS. Our findings enables ICS users to judge the benefits and harms of their medication in a more accurate manner and helps to address concerns and uncertainty surrounding the exact risk of skeletal adverse effects.
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